Caov-3Homo sapiens (Human)Cancer cell line
Also known as: CaOv-3, CaOV-3, CAOV-3, CAOV3, CaOV3, CaOv3, Caov3, CA-OV-3, CaOV3 (S), CAVO3 (Occasionally.), CaCOV3 (Occasionally.), CACOV-3 (Occasionally.)
Quick Overview
Human high-grade serous ovarian cancer cell line for research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0201 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ovary[UBERON:UBERON_0000992] |
Donor Information
| Age | 54 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | High grade ovarian serous adenocarcinoma |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | High-Grade Serous Ovarian Cancer |
| OncoTree Code | HGSOC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000713_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Gln136Ter (c.406C>T) | Unspecified | - | PubMed=24662767 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Comparative properties of five human ovarian adenocarcinoma cell lines.
Buick R.N., Pullano R., Trent J.M.
Cancer Res. 45:3668-3676(1985).
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Berchuck A., Futreal P.A.
Gynecol. Oncol. 70:13-16(1998).
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
Lau K.-M., Mok S.C., Ho S.-M.
Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Auersperg N., Birrer M.J.
Oncogene 21:4435-4447(2002).
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
Knudsen B.S., Hanash S.M.
PLoS ONE 3:E2425-E2425(2008).
S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.
Am. J. Clin. Pathol. 132:846-856(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Oncol. Rep. 23:1021-1026(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Genomic complexity and AKT dependence in serous ovarian cancer.";
Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Cancer Discov. 2:56-67(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Lessey B.A., Jordan V.C., Bradford A.P.
Gynecol. Oncol. 127:241-248(2012).
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mills G.B., Hennessy B.T.
Mol. Oncol. 7:567-579(2013).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
Type-specific cell line models for type-specific ovarian cancer research.
Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
PLoS ONE 8:E72162-E72162(2013).
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Helleman J.
PLoS ONE 9:E103988-E103988(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Noonan A.M., Annunziata C.M.
Gynecol. Oncol. 142:332-340(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Nat. Commun. 7:12645.1-12645.14(2016).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro relies on translational regulation of CSAG2.
Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.
Front. Pharmacol. 11:600994.1-600994.10(2020).
Chemoresistant cancer cell lines are characterized by migratory, amino acid metabolism, protein catabolism and IFN1 signalling perturbations.
Hoffmann P., Klingler-Hoffmann M.
Cancers (Basel) 14:2763.1-2763.24(2022).